NASDAQ:ATHA

Athira Pharma (ATHA) Stock Forecast, Price & News

$3.02

+0.27 (+9.82%)

(As of 06/2/2023 ET)

Compare

Today's Range: $2.75
▼
$3.02
50-Day Range: $2.26
▼
$3.04
52-Week Range: $2.22
▼
$9.92

Volume: 326,682 shs
Average Volume: 151,258 shs
Market Capitalization: $114.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Athira Pharma MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 231.1% Upside
$10.00 Price Target
Short Interest: Healthy
5.81% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.89
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$12,000 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.34) to ($3.62) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

237th out of 980 stocks

Biological Products, Except Diagnostic Industry

32nd out of 163 stocks

3.3

Analyst's Opinion

Consensus Rating
Athira Pharma has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Athira Pharma has a forecasted upside of 231.1% from its current price of $3.02.
Amount of Analyst Coverage
Athira Pharma has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
5.81% of the float of Athira Pharma has been sold short.
Short Interest Ratio / Days to Cover
Athira Pharma has a short interest ratio ("days to cover") of 9.6.
Change versus previous month
Short interest in Athira Pharma has recently decreased by 5.53%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Athira Pharma does not currently pay a dividend.
Dividend Growth
Athira Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATHA.

3.3

News and Social Media Coverage

News Sentiment
Athira Pharma has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Athira Pharma this week, compared to 2 articles on an average week.
Search Interest
1 people have searched for ATHA on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Athira Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
14.90% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
58.67% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Athira Pharma are expected to decrease in the coming year, from ($3.34) to ($3.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Athira Pharma is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Athira Pharma is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Athira Pharma has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Athira Pharma (NASDAQ:ATHA) Stock

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Receive ATHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter.

ATHA Stock News Headlines

June 1, 2023 | americanbankingnews.com

Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Update

May 31, 2023 | finance.yahoo.com

Athira Pharma to Participate in Upcoming June Conferences

June 4, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 30, 2023 | markets.businessinsider.com

Stifel Nicolaus Remains a Hold on Athira Pharma (ATHA)

May 22, 2023 | markets.businessinsider.com

Athira Pharma Names Andrew Gengos CFO - Quick Facts

May 22, 2023 | msn.com

Athira Pharma gets new finance chief

May 22, 2023 | finance.yahoo.com

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

May 17, 2023 | markets.businessinsider.com

Athira Pharma (ATHA) Receives a Hold from Stifel Nicolaus

June 4, 2023 | Legacy Research (Affiliate) (Ad)

The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty

A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.

May 17, 2023 | americanbankingnews.com

Athira Pharma (NASDAQ:ATHA) Price Target Cut to $5.00 by Analysts at Mizuho

May 15, 2023 | msn.com

Mizuho Maintains Athira Pharma (ATHA) Buy Recommendation

May 12, 2023 | markets.businessinsider.com

JMP Securities Keeps Their Buy Rating on Athira Pharma (ATHA)

May 12, 2023 | markets.businessinsider.com

BTIG Sticks to Their Buy Rating for Athira Pharma (ATHA)

May 11, 2023 | seekingalpha.com

Athira Pharma GAAP EPS of -$0.19, revenue of $51.43M

May 11, 2023 | finance.yahoo.com

Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates

May 9, 2023 | americanbankingnews.com

Athira Pharma (ATHA) to Release Earnings on Wednesday

May 8, 2023 | finance.yahoo.com

Athira Pharma to Participate in Upcoming May Investor Conferences

May 4, 2023 | nasdaq.com

Four Biotech Stocks for ALS Awareness Month

April 29, 2023 | finance.yahoo.com

Athira Pharma, Inc. (NASDAQ:ATHA) is a favorite amongst institutional investors who own 58%

April 28, 2023 | americanbankingnews.com

Critical Contrast: Exelixis (NASDAQ:EXEL) & Athira Pharma (NASDAQ:ATHA)

April 25, 2023 | finance.yahoo.com

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

April 22, 2023 | americanbankingnews.com

Short Interest in Athira Pharma, Inc. (NASDAQ:ATHA) Rises By 8.4%

April 11, 2023 | finance.yahoo.com

Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

April 4, 2023 | americanbankingnews.com

Brokerages Set Athira Pharma, Inc. (NASDAQ:ATHA) Target Price at $14.80

April 2, 2023 | finance.yahoo.com

Trade Alert: The Independent Director Of Athira Pharma, Inc. (NASDAQ:ATHA), Grant Pickering, Has Just Spent US$60k Buying 3,193% More Shares

April 2, 2023 | americanbankingnews.com

Insider Buying: Athira Pharma, Inc. (NASDAQ:ATHA) Director Purchases 5,000 Shares of Stock

April 2, 2023 | americanbankingnews.com

BTIG Research Cuts Athira Pharma (NASDAQ:ATHA) Price Target to $10.00

See More Headlines

ATHA Price History

30 days | 90 days | 365 days | Advanced Chart

ATHA Company Calendar

Last Earnings: 3/23/2023
Today: 6/04/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ATHA
CUSIP: N/A
CIK: 1620463
Web: athira.com
Phone: 425-620-8501
Fax: N/A
Employees: 34
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.00
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +231.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-95,640,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -41.44%
Return on Assets: -38.78%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.57
Quick Ratio: 9.57

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.56 per share
Price / Book: 0.54

Miscellaneous

Outstanding Shares: 37,950,000
Free Float: 32,296,000
Market Cap: $114.61 million
Optionable: Not Optionable
Beta: 2.82

Key Executives

Dr. Mark J. Litton M.B.A. (Age 54)
MBA, Ph.D., Pres, CEO & Director
Comp: $726.32k

Ms. Rachel P. Lenington M.B.A.
Chief Operating Officer

Mr. Mark F. Worthington J.D.
Gen. Counsel & Corp. Sec.

Ms. Glenna K. Mileson (Age 63)
Chief Financial Officer

Mr. Robert Renninger
Director of Accounting & Reporting

Ms. Julie Rathbun
Head of Investor Relations

Dr. Kevin Church Ph.D. (Age 37)
Exec. VP of Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ATHA Stock - Frequently Asked Questions

Should I buy or sell Athira Pharma stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATHA shares.
View ATHA analyst ratings or view top-rated stocks.
What is Athira Pharma's stock price forecast for 2023?: 5 equities research analysts have issued 12-month price targets for Athira Pharma's stock. Their ATHA share price forecasts range from $5.00 to $20.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 231.1% from the stock's current price.
View analysts price targets for ATHA or view top-rated stocks among Wall Street analysts.
How have ATHA shares performed in 2023?: Athira Pharma's stock was trading at $3.17 at the start of the year. Since then, ATHA shares have decreased by 4.7% and is now trading at $3.02.
View the best growth stocks for 2023 here.
Are investors shorting Athira Pharma?: Athira Pharma saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 2,050,000 shares, a decrease of 5.5% from the April 30th total of 2,170,000 shares. Based on an average trading volume of 214,500 shares, the short-interest ratio is currently 9.6 days. Approximately 5.8% of the company's stock are sold short.
View Athira Pharma's Short Interest.
When is Athira Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our ATHA earnings forecast.
How were Athira Pharma's earnings last quarter?: Athira Pharma, Inc. (NASDAQ:ATHA) posted its quarterly earnings results on Thursday, March, 23rd. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.09.
What ETFs hold Athira Pharma's stock?: ETFs with the largest weight of Athira Pharma (NASDAQ:ATHA) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).iShares Neuroscience and Healthcare ETF (IBRN).

What other stocks do shareholders of Athira Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR).
When did Athira Pharma IPO?: (ATHA) raised $160 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel acted as the underwriters for the IPO and JMP Securities was co-manager.
What is Athira Pharma's stock symbol?: Athira Pharma trades on the NASDAQ under the ticker symbol "ATHA."
Who are Athira Pharma's major shareholders?: Athira Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baker BROS. Advisors LP (6.19%), BlackRock Inc. (5.99%), BML Capital Management LLC (4.92%), Simplify Asset Management Inc. (3.66%), Geode Capital Management LLC (1.67%) and Two Sigma Advisers LP (1.30%). Insiders that own company stock include Glenna Mileson, Hans Moebius, James A Johnson, Joseph Edelman, Kelly A Romano, Mark James Litton, Mark Worthington, Perceptive Advisors Llc and Rachel Lenington.
View institutional ownership trends.
How do I buy shares of Athira Pharma?: Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Athira Pharma's stock price today?: One share of ATHA stock can currently be purchased for approximately $3.02.
How much money does Athira Pharma make?: Athira Pharma (NASDAQ:ATHA) has a market capitalization of $114.61 million. The company earns $-95,640,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis.
How can I contact Athira Pharma?: The official website for the company is athira.com. The company can be reached via phone at 425-620-8501 or via email at ir@athira.com.

This page (NASDAQ:ATHA) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial